Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1530 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1530 | DRUG | Administered po at escalating doses (10 cohorts) |
Inclusion Criteria: * adult patients, \>=18 years of age; * cancer not amenable to curative treatment (ie advanced and/or metastatic); * measurable or evaluable disease; * adequate cardiac, hepatic and renal function. Exclusion Criteria: * patients with known CNS metastases; * serious cardiovascu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
RG1530 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Roche Holding AG for use in oncology, the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
The specific molecular target of RG1530 has not been disclosed in available information. As a small molecule in oncology, it is designed to interact with cellular components involved in tumor growth, but the exact target is not publicly specified.
RG1530 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
RG1530 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a multiple ascending dose study in patients with advanced solid tumors. The drug is still investigational and has not been approved by regulatory authorities for any use.
RG1530 has been studied in one clinical trial, identified as NCT00493155. This was a Phase 1, multiple ascending dose study conducted in the United States, enrolling 48 patients with advanced solid tumors. The trial has been completed and was uncontrolled, meaning there was no comparison group.
Yes, RG1530 is also known as R1530. The clinical trial NCT00493155, titled 'A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors,' refers to the drug as R1530, confirming that RG1530 and R1530 are the same investigational compound.